



DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 4, 2014 – The shareholders approved all proposals of the Board of Directors at the 9th Annual General Meeting of DOTTIKON ES HOLDING AG in Baden. 76 present shareholders represented 1'069'101 voting rights and therefore 88.2% of the total of 1'211'807 registered shares with voting rights.

The Annual Report, financial statements 2013/14, and the Group financial statements 2013/14 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Discharge for the business year 2013/14 was granted to the responsible Board of Directors and Management. Carrying forward the entire retained earnings 2013/14 to new account was approved, as well as the reduction of share capital by reduction of nominal value per registered share by CHF 4.90 to CHF 0.10. The revision of the by-laws, due to reduction of nominal value and the adaptations of the Ordinance against Excessive Compensation at Listed Companies (VegüV), was accepted. The previous Chairman of the Board of Directors Dr. Markus Blocher was confirmed for another term of one year. Dr. Thomas Früh was reelected for a term of one year as Deputy Chairman and Dr. Alfred Scheidegger as member of the Board, respectively. All three Board members were elected for a term of one year as members of the Compensation Committee. Dr. Markus Blocher was elected as its Chairman and Dr. Thomas Früh as its deputy. The proposed maximum amounts of prospective remunerations for the entire Board of Directors and Senior Management, respectively, were approved. Peter E. Widmer, lic. iur. and notary, was appointed as independent proxy for the next 10th Annual General Meeting. Deloitte AG, Zurich, was reelected for another term of one year as external auditor.

The reduction of nominal value per share will be paid out approximately at the end of September/beginning of October 2014 after registration of the reduction of share capital into the commercial register after threefold publication of the notice to creditors that are required by law. Details to the exact due dates will be published in due time.

DOTTIKON ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and is positioning itself as strategic development and manufacturing partner. Its safety culture created over the last 100 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons.



dottikon

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent communication with customers.

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.

CEO

Dottikon ES Holding AG

Tel +41 56 616 82 01

Fax +41 56 616 89 45

investor-relations@dottikon.com